Loading...
Publication
Avaliação de Rácios Hematológicos em Tumores Mamários Felinos
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 255.39 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Os tumores mamários estão entre as neoplasias mais frequentes em gatas. Na sua maioria são malignos e
apresentam um comportamento biológico agressivo, tendo a maioria dos animais afetados um curto período
de sobrevivência após o diagnóstico. A determinação de fatores de prognóstico é importante em oncologia
humana e veterinária, uma vez que é fundamental na predição da evolução da doença e para a determinação
de decisões terapêuticas. Na prática clínica, principalmente em oncologia veterinária, a existência de fatores
de prognóstico que sejam facilmente acessíveis, de fácil interpretação e que apresentem um baixo custo são
extremamente importantes. Diferentes alterações nos parâmetros e rácios hematológicos foram descritos
como potenciais fatores de prognóstico em vários tumores em medicina humana e veterinária. No entanto, a
informação disponível em oncologia felina é escassa. Este estudo teve como objetivo avaliar o valor
prognóstico de diferentes rácios hematológicos (rácio neutrófilo-linfócito, rácio eritrócito-plaquetas, rácio
hemoglobina-eritrócito, rácio plaqueta-linfócito, rácio linfócito-monócito, rácio linfócito-eritrócito e rácio
neutrófilo-eritrócito), em carcinomas mamários felinos. Para este estudo foram selecionadas 66 gatas
apresentadas em cinco centros de atendimento médico-veterinário de Portugal no período entre 2015 e 2021
com diagnóstico de carcinoma mamário em estadio clínico I, II e III (determinado de acordo com a
classificação modificada da Organização Mundial de Saúde) e que foram submetidas a mastectomia. As
medianas do tempo livre de doença (DFI) e do tempo de sobrevivência tumoral específica (TSS) da população
em estudo foram de 285 dias e 414 dias, respetivamente. A estatística univariada mostrou que valores mais
elevados do rácio neutrófilo-eritrócito (NRR) (NRR>0,75) estavam significativamente associados a um menor
tempo de sobrevivência dos animais (p=0,001). Os nossos resultados sugerem que o NRR pode ser utilizado
como marcador de prognostico pré-cirúrgico não invasivo. No entanto mais estudos são necessários para
comprovar o uso clínico como biomarcador de prognóstico de carcinomas mamários felinos.
Mammary tumors are among the most frequent neoplasms in cats. Most are malignant and have an aggressive biological behavior, with most affected animals having a short survival period after diagnosis. The determination of prognostic factors is important in human and veterinary oncology, as it is fundamental in predicting the course of the disease and for determining therapeutic decisions. In clinical practice, especially in veterinary oncology, the existence of prognostic factors that are easily accessible, easy to interpret and have a low cost are extremely important. Different changes in hematological parameters and ratios have been described as potential prognostic factors in various tumors in human and veterinary medicine. However, the information available in feline oncology is scarce. This study aimed to evaluate the prognostic value of different hematological ratios (neutrophil-lymphocyte ratio, erythrocyte-platelet ratio, hemoglobin-erythrocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio, lymphocyte-erythrocyte ratio and neutrophil-erythrocyte ratio), in feline mammary carcinomas. For this study, 66 cats presented at five veterinary medical care centers in Portugal between 2015 and 2021 with a diagnosis of breast carcinoma in clinical stages I, II and III (determined according to the modified classification of the World Health Organization) were selected. ) and who underwent mastectomy. The median disease-free time (DFI) and tumor-specific survival time (TSS) of the study population were 285 days and 414 days, respectively. Univariate statistics showed that higher values of the neutrophil-erythrocyte ratio (NRR) (NRR>0.75) were significantly associated with a shorter animal survival time (p=0.001). Our results suggest that the NRR can be used as a non-invasive pre-surgical prognostic marker. However, more studies are needed to prove its clinical use as a prognostic biomarker of feline mammary carcinomas.
Mammary tumors are among the most frequent neoplasms in cats. Most are malignant and have an aggressive biological behavior, with most affected animals having a short survival period after diagnosis. The determination of prognostic factors is important in human and veterinary oncology, as it is fundamental in predicting the course of the disease and for determining therapeutic decisions. In clinical practice, especially in veterinary oncology, the existence of prognostic factors that are easily accessible, easy to interpret and have a low cost are extremely important. Different changes in hematological parameters and ratios have been described as potential prognostic factors in various tumors in human and veterinary medicine. However, the information available in feline oncology is scarce. This study aimed to evaluate the prognostic value of different hematological ratios (neutrophil-lymphocyte ratio, erythrocyte-platelet ratio, hemoglobin-erythrocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio, lymphocyte-erythrocyte ratio and neutrophil-erythrocyte ratio), in feline mammary carcinomas. For this study, 66 cats presented at five veterinary medical care centers in Portugal between 2015 and 2021 with a diagnosis of breast carcinoma in clinical stages I, II and III (determined according to the modified classification of the World Health Organization) were selected. ) and who underwent mastectomy. The median disease-free time (DFI) and tumor-specific survival time (TSS) of the study population were 285 days and 414 days, respectively. Univariate statistics showed that higher values of the neutrophil-erythrocyte ratio (NRR) (NRR>0.75) were significantly associated with a shorter animal survival time (p=0.001). Our results suggest that the NRR can be used as a non-invasive pre-surgical prognostic marker. However, more studies are needed to prove its clinical use as a prognostic biomarker of feline mammary carcinomas.
Description
Keywords
Carcinoma mamário Fatores de prognóstico Gata Rácios hematológicos Rácio neutrófilo-eritrócito Cat Hematological ratios Mammary tumours Prognostic factors Neutrophil-erythrocyte ratio